Azamian Bobak R.'s Form 4 filing
Tarsus Pharmaceuticals, Inc. (TARS) · filed Mar 20, 2025
- Accession no.
- 0001819790-25-000055
- Filed
- Mar 20, 2025
- Trade date
- Mar 18-20, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions. Open-market sales total $1.16M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Azamian Bobak R.CIK 0001827672 | Director, Officer (President/CEO and Board Chair) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 18, 2025 | Common Stock | SSaleDisposed | −7,131 | $46.29 | −$330,093.99 | 70,720 | Direct | |
| Mar 19, 2025 | Common Stock | SSaleDisposed | −8,551 | $47.40 | −$405,317.4 | 62,169 | Direct | |
| Mar 20, 2025 | Common Stock | SSaleDisposed | −8,534 | $50.11 | −$427,638.74 | 53,635 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.